An interventional study of C-Mill technology treadmill equipped with semi-immersive VR and C-Mill treatment without semi-immersive virtual reality (VR) in Parkinson Disease, sponsored by IRCCS Centro Neurolesi Bonino Pulejo. Recruiting at 1 site in Italy. Open to participants aged 40 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-02-25.
Sponsored by IRCCS Centro Neurolesi Bonino Pulejo · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Parkinson Disease by IRCCS Centro Neurolesi Bonino Pulejo — 6 open to participants now, 8 under way, none of them phase 3. Parkinson Disease · IRCCS Centro Neurolesi Bonino Pulejo.
Among the 13 studies in Parkinson Disease by IRCCS Centro Neurolesi Bonino Pulejo, this one is the 7th largest by planned enrollment, is one of 4 that started in 2025, is one of 13 with no phase, and was the 13th registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →6 of the 13 studies in Parkinson Disease by IRCCS Centro Neurolesi Bonino Pulejo are open now, in 1 country. Recruiting first, the newest first:
IRCCS Centro Neurolesi Bonino Pulejo · Sites in Italy
Ages 18–75
IRCCS Centro Neurolesi Bonino Pulejo · Sites in Italy
Ages 40–80
IRCCS Centro Neurolesi Bonino Pulejo · Sites in Italy
Ages 18–70 · Healthy volunteers
IRCCS Centro Neurolesi Bonino Pulejo · Sites in Italy
Ages 45–80
IRCCS Centro Neurolesi Bonino Pulejo · Sites in Italy
Ages 18–90 · Healthy volunteers
By country, each count listing its studies:
Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 40 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 4 started in 2025.
This study's planned enrollment of 60 is above the median of 40 across 3,360 interventional studies indexed under Parkinson Disease.
Median enrollment 60 across the 13 interventional studies. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
IRCCS Centro Neurolesi Bonino Pulejo is the lead sponsor of 67 studies on the registry; 30 are open to participants now.
2 of the studies in Parkinson Disease by IRCCS Centro Neurolesi Bonino Pulejo that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06838975IRCCS Centro Neurolesi Bonino PulejoVirtual Reality Rehabilitation for Cognitive, Emotional, and Motor Recovery in Neurological Disorders | 2027-09-29 |
| NCT07434089IRCCS Centro Neurolesi Bonino PulejoImpact of C-Mill Rehabilitation on the Gut-Brain Axis in Parkinson's Disease | 2027-10-20 |
Add all 2 to your calendar (.ics) → With an account.
Among the 13 studies in Parkinson Disease by IRCCS Centro Neurolesi Bonino Pulejo, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The GM-REHAB-2025 study aims to evaluate the impact of physiotherapy interventions using the C-Mill treadmill, with and without semi-immersive virtual reality, on gut microbiota and metabolic parameters in patients with Parkinson's disease. Three groups will be involved: one undergoing conventional physiotherapy, one treated with the C-Mill without virtual reality (VR), and one treated with C-Mill technology combined with VR. Clinical assessments and the collection of biological samples (stool, serum, and plasma) will be carried out at three time points: at baseline, at the end of treatment (21 days), and after 3 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
includes 20 patients with PD undergoing C-Mill treatment combined with semi-immersive virtual reality (VR). This group will participate in 12 training sessions, each lasting 45 minutes, four times a week for three weeks. Gait training in each session will include exercises such as path with obstacles, tandem walking, slalom, and walking at varying speeds, all enhanced with semi-immersive VR scenarios projected on the treadmill's floor. The VR component will feature visual obstacles, such as virtual traffic cones or country paths, in conjunction with audio-visual stimuli to promote engagement and guide movement.
Device: C-Mill technology treadmill equipped with semi-immersive VR
Consists of 20 patients with Parkinson's Disease (PD) undergoing C-Mill treatment as a standalone therapy, without the integration of virtual reality (VR). Participants will complete 12 training sessions, each lasting 45 minutes, four times a week for three weeks. The training sessions will include exercises such as tandem walking, slalom walking, obstacle courses, and walking at varying speeds, all designed to enhance gait and balance.
Device: C-Mill treatment without semi-immersive virtual reality (VR)
Consists of 20 patients with PD, who will undergo conventional physiotherapy training under the manual guidance and supervision of a physiotherapist. The rehabilitation program will include weight-shifting exercises, as well as monopodal and bipodal balance exercises. Gait training will incorporate obstacle courses (e.g., bricks, boxes) of varying shapes and colors, or paths created by the physiotherapist using furniture and equipment (e.g., chairs, traffic cones, sandbags). Patients will also perform slalom walking exercises, with auditory stimuli (e.g., music, therapist's voice) and visual cues (e.g., colored tape on the floor) to guide the exercises, adjusting their walking speed based on the auditory cues provided by the therapist.
Other: Conventional physiotherapy training
C-Mill treatment combined with semi-immersive virtual reality (VR). The VR component will feature visual obstacles, such as virtual traffic cones or country paths, in conjunction with audio-visual stimuli to promote engagement and guide movement.
C-Mill treatment will be administrated as a standalone therapy, without the integration of virtual reality (VR).
Will be carried under the manual guidance and supervision of a physiotherapist. The rehabilitation program will include weight-shifting exercises, as well as monopodal and bipodal balance exercises.
Relative abundance of bacterial and fungal taxa in fecal samples
Relative abundance of bacterial and fungal taxa determined by sequencing the V3-V4 regions of the 16S rRNA and ITS1-IT2 regions from fecal samples. Unit of measurement: percentage of total sequencing reads(%).
Time frame: From enrollment to the 3 months follow-up
Alpha Diversity of the Gut Microbiota
Within-sample microbial diversity derived from sequencing of the V3-V4 regions of the 16S rRNA gene and ITS1-ITS2 regions from fecal samples, expressed as an alpha diversity index. Unit of Measure: alpha diversity index value. Higher values indicate greater microbial diversity.
Time frame: From enrollment to the 3 months follow-up
Beta Diversity of the Gut Microbiota
Between-sample microbial community derived from the sequencing of V3-V4 regions of the 16S rRNA and ITS1-ITS2 and expressed as a beta diversity distance. Unit of Measure: beta diversity distance. Higher values indicate greater dissimilarity between samples.
Time frame: From enrollment to the 3 months follow-up
Distance Covered During the 6-Minute Walk Test
Functional walking capacity measured as the total distance walked during the 6-Minute Walk Test. Unit of Measure: meters. Higher values indicate better walking capacity.
Time frame: From enrollment to the 3 months follow-up
Time Required to Complete the 10-Meter Walk Test
Walking ability assessed by measuring the time required to walk 10 meters at usual pace. Unit of Measure: seconds. Lower values indicate better walking performance.
Time frame: From enrollment to the 3 months follow-up
Time Required to Complete the Timed Up and Go Test
Mobility and fall risk assessed by the time needed to stand up, walk 3 meters, turn, return, and sit down. Unit of Measure: seconds. Lower values indicate better functional mobility.
Time frame: From enrollment to the 3 months follow-up
Balance Performance Assessed by the Berg Balance Scale
Balance measured using the Berg Balance Scale (range: 0-56). Higher scores indicate better balance and lower fall risk. Unit of Measure: total score.
Time frame: From enrollment to the 3 months follow-up
Balance and Gait Performance Assessed by the Tinetti Scale
Balance and gait evaluated using the Tinetti Scale (range: 0-29). Higher scores indicate better mobility and lower fall risk. Unit of Measure: total score.
Time frame: From enrollment to the 3 months follow-up
Fear of Falling Assessed by the Short Falls Efficacy Scale-International
Concern about falling measured using the Short Falls Efficacy Scale-International (range: 7-28). Higher scores indicate greater fear of falling. Unit of Measure: total score.
Time frame: From enrollment to the 3 months follow-up
Motor Symptom Severity Assessed by the MDS-UPDRS Part III (Motor Examination)
Motor impairment evaluated using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III, the Motor Examination section. Total score range from 0 to 132. Unit of Measure: total score. Higher scores indicate worse motor impairment.
Time frame: From enrollment to the 3 months follow-up
Functional Independence Assessed by the Functional Independence Measure
Global functional status assessed using the Functional Independence Measure (range: 18-126). Higher scores indicate greater independence in daily activities. Unit of Measure: total score.
Time frame: From enrollment to the 3 months follow-up
Severity of Constipation Assessed by the Constipation Scoring System
Constipation severity measured using the Constipation Scoring System questionnaire (range: 0-30). Higher scores indicate more severe constipation. Unit of Measure: total score.
Time frame: From enrollment to the 3 months follow-up
Serum Concentration of TNF-α
Serum TNF-α, a key pro-inflammatory cytokine, measured by ELISA to assess systemic inflammatory activation. Unit of Measure: pg/mL
Time frame: From enrollment to the 3 months follow-up
Serum Concentration of IL-1β
Serum IL-1β, a pro-inflammatory cytokine involved in immune response, measured by ELISA. Unit of Measure: pg/mL
Time frame: From enrollment to the 3 months follow-up
Serum Concentration of IL-6
Serum IL-6, a pro-inflammatory cytokine that mediates systemic inflammation, measured by ELISA. Unit of Measure: pg/mL
Time frame: From enrollment to the 3 months follow-up
Serum Concentration of IL-10
Serum IL-10, an anti-inflammatory cytokine that regulates immune responses, measured by ELISA. Unit of Measure: pg/mL
Time frame: From enrollment to the 3 months follow-up
Serum Concentration of IL-4
Serum IL-4, an anti-inflammatory cytokine involved in immune modulation, measured by ELISA. Unit of Measure: pg/mL
Time frame: From enrollment to the 3 months follow-up
Serum Concentration of FNDC5
Serum FNDC5, a metabolic peptide measured by ELISA. Unit of Measure: ng/mL
Time frame: From enrollment to the 3 months follow-up
Serum Concentration of Adiponectin
Serum Adiponectin, a metabolic peptide measured by ELISA. Unit of Measure: ng/mL
Time frame: From enrollment to the 3 months follow-up
Serum Concentration of Reduced Glutathione
Serum Reduced Glutathione (GSH), a key antioxidant reflecting oxidative stress status, measured by ELISA. Unit of Measure: µmol/L
Time frame: From enrollment to the 3 months follow-up
Serum Concentration of Oxidized Glutathione
Serum Oxidized Glutathione (GSSG), the oxidized form of glutathione indicating oxidative stress, measured by ELISA. Unit of Measure: µmol/L
Time frame: From enrollment to the 3 months follow-up
Serum Concentration of High-Sensitivity C-Reactive Protein
Serum High-Sensitivity C-Reactive Protein (hs-CRP), an acute-phase protein reflecting systemic inflammation, measured by ELISA. Unit of Measure: mg/L
Time frame: From enrollment to the 3 months follow-up
Started Oct 2025 (actual). Primary completion is estimated for Oct 2027, 24 months after the start.
Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 24 months is close to that.
Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
IRCCS Centro Neurolesi Bonino Pulejo